Liver study checks how vorasidenib behaves in sick patients
NCT ID NCT07250633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looks at how a single dose of the drug vorasidenib is handled by the body in people with severe liver impairment compared to those with normal liver function. About 20 participants will take one pill and be monitored for up to 77 days with blood tests and heart checks. The goal is to gather safety and drug-level information, not to treat a disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vorasidenib
- What this could lead to
- If successful, this study could help doctors understand how to safely dose vorasidenib in patients with severe liver disease.
- What could go wrong
- This is a very early, small study (20 people) focused on safety and drug levels, not on treating any disease. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NORMAL HEPATIC FUNCTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
American Research Corporation
RECRUITINGSan Antonio, Texas, 78215, United States
-
Arizona Clinical Trials
RECRUITINGChandler, Arizona, 85225, United States
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.